Virta Health is a digital health company on a mission to reverse type 2 diabetes and obesity in 100 million people. Founded in 2014 by Sami Inkinen, Dr. Stephen Phinney, and Dr. Jeff Volek, Virta pairs a nutrition-first, low-carbohydrate clinical protocol with a Continuous Remote Care platform - a mobile app, dedicated physicians and health coaches, and AI-driven personalization - to lower blood sugar, cut medications, and produce durable weight loss without relying on costly drugs or surgery. Sold to employers and health plans on a value-based, outcomes-guaranteed model, Virta has treated over 100,000 members and surpassed $160M in annualized revenue.
Forta is a San Francisco-based virtual ABA therapy company that pairs board-certified behavior analysts with families across 47 states, using AI-assisted clinical algorithms to deliver autism care without the years-long waitlists that define the industry.
House Rx is a San Francisco-based healthcare technology company that partners with specialty clinics to enable medically integrated dispensing (MID) - a model where physicians, pharmacists, nurses, and care coordinators work together as one unified team. Founded in 2021 by Flatiron Health veterans Ogi Kavazovic and Tesh Khullar, the company builds AI-enabled pharmacy management software that keeps specialty medications dispensed at the point of care, cutting average time-to-therapy from 15.5 days to 3.5 days and achieving 95% medication adherence. With $100M raised across Seed, Series A, and Series B rounds, House Rx serves 80 clinic sites, 1,000+ providers, and nearly 61,000 patients, processing approximately $1.5 billion in specialty prescriptions annually.
Adnan Iqbal is the Co-Founder and CEO of Luma Health, a San Mateo-based healthcare technology company that has built an AI-native Patient Success Platform used by 750+ healthcare organizations, 100 million patients, and 500,000+ providers. A second-generation Pakistani-American and serial entrepreneur, Iqbal studied environmental biology at UC Berkeley, earned an MPhil in BioScience from Cambridge University, and an MS/MBA from Stanford GSB. Before Luma, he spent five years in management at Genentech and co-founded AutoTB, a tuberculosis diagnostic startup that won both Cambridge and UC Berkeley entrepreneurship competitions. Luma Health has raised $160 million in funding and enabled $3.2 billion in healthcare revenue.
Ian Christopher is the Co-Founder and Chief Engineer of Qventus, the AI-powered hospital operations platform backed by KKR and Bessemer Venture Partners. A Stanford-trained computational engineer, he co-built Qventus from a 2012 YC startup into a $400M+ company that automates how hospitals manage patient flow, surgical scheduling, and care coordination - reducing staff burnout and cutting length of stay for major health systems across the US.
Keith Carter is a healthcare technology operator with deep roots in medical imaging and surgical data infrastructure. Currently VP of Implementations & Integrations at Caresyntax - the AI-powered surgical intelligence platform used in 3,500+ operating rooms worldwide - he also serves as CEO of Cloud9PACS.com, a digital PACS system he built from the ground up. Carter's career traces the arc of healthcare IT: from PACS architect at Medlink to running his own imaging solutions company, to joining one of the most-funded surgical AI ventures in the industry. He is based in Hattiesburg, Mississippi.
Khanh Nguyen is the CEO of Cozeva, the operating system for value-based care that manages over 25 million lives across 97,000+ providers. A PharmD from UCSF with 15+ years pioneering payer-provider collaboration, she led Cozeva to a reported $480M merger with Vatica Health in 2025, combining the #1-rated Best in KLAS risk adjustment platform with Cozeva's #1 quality platform - creating the most comprehensive value-based care enablement company in the U.S.
Tassos Gianakakos is a Greek-American biotech entrepreneur and the co-founder, CEO, and Chair of Kardigan, a cardiovascular drug discovery company he built from the ashes of MyoKardia — the precision-medicine heart company he led to a $13.1 billion acquisition by Bristol Myers Squibb in 2020. At Kardigan, he is applying the same playbook: marrying real-world clinical data, AI tools, and deep cardiovascular biology to deliver personalized medicines for heart disease — a field he believes is where oncology was 20 years ago. With $554 million raised and three late-stage clinical programs underway, Gianakakos is on a mission to make cardiovascular disease preventable and curable.